29311-94-2Relevant articles and documents
BH4 ANTAGONISTS AND METHODS RELATED THERETO
-
Page/Page column 33, (2015/11/27)
The disclosure relates to BH4 inhibitors and therapeutic uses relates thereto. In certain embodiments, the disclosure relates to methods of treating or preventing cancer, such as lung cancer, comprising administering therapeutically effective amount of a pharmaceutical composition comprising a compound disclosed herein or pharmaceutically acceptable salt to a subject in need thereof.
Preparation of 1,4-bis(hydroxylakylamino)anthraquinones as protein kinase C inhibitors.
-
, (2008/06/13)
-
Novel Non-Cross Resistant Diaminoanthraquinones as Potential Chemotherapeutic Agents
Jiang, Jack B.,Johnson, Mary George,Defauw, Jean M.,Beine, Tracey M.,Ballas, Lawrence M.,et al.
, p. 4259 - 4263 (2007/10/02)
A novel series od diaminoanthraquinones was discovered initially as protein kinase C inhibitors with IC50s in the 50-100 μM range.They exhibited potent tumor cell growth inhibitory activity in vitro without cross resistance to adriamycin.Further evaluation of two of the most active compounds NSC 639365 (3) and NSC 639366 (4) in human tumor cloning assay showed potent cytocidal activity.The results suggest therapeutical potentials against human tumors.